How much revenue does Hualan Biological Engineering make?

Hualan Biological Engineering reported 4.38 billion CNY in revenue for fiscal year 2024, down 18.0% from 5.34 billion CNY in fiscal year 2023. In Q2 2025 revenue was 930.59 million CNY.

What is Hualan Biological Engineering's largest business segment?

Blood Product, with 3.39 billion CNY or 74% of segment revenue in fiscal year 2025. Next: Vaccine Product (26%) and Others (under 1%).

Where does Hualan Biological Engineering make most of its revenue?

China: 100% of revenue by region in fiscal year 2025, followed by Overseas (under 1%).

What companies are similar to Hualan Biological Engineering?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Livzon Pharmaceutical Group Inc. (000513.SZ), Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS), Beijing Tiantan Biological Products Co., Ltd. (600161.SS), Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ).

Hualan Biological Engineering Inc. (002007.SZ) Stock

About Hualan Biological Engineering Inc.

Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as in...

At a glance

Hualan Biological Engineering reported revenue of 4.38 billion CNY for fiscal year 2024, down 18.0% from fiscal year 2023, and net income of 1.09 billion CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 930.59 million CNY, up 7.5% from a year before. Its largest business segment, Blood Product, brought in 74% of segment revenue in fiscal year 2025; China was the largest region with 100%.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.